Reducing opioid exposure after cardiac surgery with parasternal intercostal plane blocks (EPOCH CardioLink-10)—authors' response Authors: Ahmad Alli, C David Mazer, Subodh Verma, EPOCH CardioLink-10 Investigators Published: 2026 We thank Mehta and colleagues1 for their thoughtful and complimentary comments regarding EPOCH CardioLink-10.2 Although further direct comparisons of single-injection and catheter-based superficial parasternal intercostal plane (SPIP) blockade may be warranted, we believe that several distinctions are important when interpreting our findings and the available evidence. EPOCH CardioLink-10 was designed to determine whether a pragmatic, catheter-based SPIP regimen reduces postoperative opioid exposure versus placebo, not to isolate bolus versus catheter-dosing contributions, nor establish superiority over single-injection technique. Our findings should not be interpreted as a direct continuous-versus-single-injection comparison; equally, that absence does not support a preference for single-injection blockade. Our intervention was more accurately a repeated intermittent-bolus catheter regimen than a conventional continuous infusion: an initial 20 mL/side bolus, low basal infusion (0.1–1 mL/h/side), plus 5 mL boluses every 3–4 h for 48 h, addressing the limited duration and cephalocaudal spread of single injections. This produced a significant 20.7 MME reduction in cumulative 72-h opioid use and an almost 50% reduction in high opioid exposure (>200 MMEs), with similar pain control. EPOCH CardioLink-10 was also conducted across four Canadian centres, unlike the single-centre trials in the correspondents' Table 1. Single-centre trials have been reported to systematically overestimate treatment effects relative to multicentre trials.3 In our study, multimodal analgesia followed established local enhanced-recovery pathways at each centre. Non-opioid medications were not protocol-mandated uniformly. This intentional pragmatic design enhanced applicability across centres with differing, guideline–concordant pathways. Randomisation was expected to have distributed these co-interventions between groups. We agree that additional reporting of both opioid and non-opioid analgesic exposure would be of interest and these will be explored in subsequent analyses. Safety is central to catheter-based regional techniques. The maximum ropivacaine dose used in EPOCH CardioLink-10 was conservatively calculated to be approximately 592 mg/48 h. This dose was lower than several previously reported continuous or repeated-bolus SPIP regimens, yet still produced a significant reduction in opioid consumption, suggesting meaningful analgesic benefit is achievable without higher-dose regimens that carry greater theoretical local anaesthetic systemic toxicity (LAST) risk. No cases of LAST, allergic reactions, pneumothorax, vascular injury, haematoma, infection, or other serious block-related complications occurred among 318 modified intention-to-treat participants. Although plasma ropivacaine concentrations were not routinely measured, the absence of clinically apparent toxicity is reassuring. Pharmacokinetic studies and continued surveillance remain warranted, particularly for higher-concentration or higher-volume regimens. The studies summarised by Mehta and colleagues also illustrate the limitations of making firm clinical recommendations based on their findings.4, 5, 6 Specifically, the studies differ substantially in catheter design, anaesthetic concentration, dosing frequency, infusion volume, multimodal analgesia, primary outcome, and sample size, thereby yielding heterogeneous results. The 80-participant trial cited as showing no benefit of continuous blockade was powered for pain during coughing at 24 h, not opioid exposure, so it should not be read as definitive evidence of equivalence.3 Non-inferiority conclusions are generally not appropriate from small, negative superiority trials. We agree that the incremental efficacy, safety, feasibility, and cost-effectiveness of single-injection versus catheter-based SPIP blockade remain unanswered research questions. Until adequately powered head-to-head trials are completed, technique selection should reflect institutional expertise, expected duration of pain, patient characteristics, available monitoring, and the broader enhanced-recovery pathway. EPOCH CardioLink-10 clearly demonstrates that a repeated-bolus catheter-based SPIP strategy can safely reduce early postoperative opioid exposure without compromising analgesia or recovery. As the only multicentre trial to date to address this question, EPOCH CardioLink-10 adds robust data to the current body of evidence, which we believe still does not support nor justify a conclusion that single-injection blockade should be the preferred technique for most patients. Contributors AA—writing, original draft and writing, review & editing; CDM—writing, review & editing; SV—writing, review & editing. Declaration of interests AA reports honoraria for lectures from Edwards Lifesciences. CDM has received advisory board honoraria/consulting fees from Amgen, Alexion, AstraZeneca, BioAge, Biotest, Boehringer Ingelheim, Cardior, Cytosorbents, Delex, Grifols, ONA, PhaseBio, Sandoz, Trimedic Therapeutics, and Werfen as well as data safety monitoring board stipends from Beth Israel Deaconess Medical Center, Cerus, Takeda and VarmX. SV reports receiving grants and/or research support and/or speaking honoraria from and/or acting as an advisor for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Heart Research Centre, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics Inc., Humber River Health, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, PhaseBio, S & L Solutions Event Management Inc., Sanofi and Sun Pharma.